NICE TAs

01/05/2020

TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer

01/05/2020

TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

01/05/2020

TA466: Baricitinib for moderate to severe rheumatoid arthritis

01/05/2020

TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant

30/04/2020

TA485: Sarilumab for moderate to severe rheumatoid arthritis

30/04/2020

TA511: Brodalumab for treating moderate to severe plaque psoriasis

30/04/2020

TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy

29/04/2020

TA480: Tofacitinib for moderate to severe rheumatoid arthritis

29/04/2020

TA616: Cladribine for treating relapsing–remitting multiple sclerosis

29/04/2020

TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis

29/04/2020

TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

29/04/2020

TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma

29/04/2020

TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

29/04/2020

TA512: Tivozanib for treating advanced renal cell carcinoma

29/04/2020

TA555: Regorafenib for previously treated advanced hepatocellular carcinoma

29/04/2020

TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer

29/04/2020

TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer

29/04/2020

TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C

29/04/2020

TA588: Nusinersen for treating spinal muscular atrophy

29/04/2020

TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours